ESG risk score 18.67
Environmental score 2.16
Social score 11.77
Governance score 4.74
ESG risk category Low
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+
Novo Nordisk B A/S
000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol NOVOb:xcse
Currency DKK
NASDAQ OMX Copenhagen
Open Closed
15 minutes delayed
Data provided by 
This information is not currently available for this instrument. Refresh the page or try again later.
Want to start investing?
Trade stocks with a broker trusted by over 1.5 million clients. Investing involves risk. You may lose some or all of your investment.
Chart
This information is not currently available for this instrument. Refresh the page or try again later.
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
This information is not currently available for this instrument. Refresh the page or try again later.
Returns
Year to date (YTD) -7.76%
1 year -32.48%
3 years -48.08%
Data provided by 
Key stats
Price/earnings (LTM) 10.93
Dividend yield (LTM) 3.9%
EPS (LTM) 27.44
Volatility (30 days) 40.42%
Data provided by
Analyst consensus
Average rating Hold
Rating Analysts
Buy
10
Overweight
1
Hold
22
Underweight
1
Sell
2
Target price 308.5
Implied return 2.83%
Last updated 06-May-2026
Data provided by
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Data provided by 
/ 
/ Financials
Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX
About Novo Nordisk B A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sector Healthcare
Industry -
Market cap 1,333bn
Data provided by /
/ Novo Nordisk A/S is a Danish multinational pharmaceutical company specialising in treatments for diabetes, obesity, and other severe chronic diseases. Founded in 1923 and headquartered in Bagsværd, Denmark, the company is one of the largest producers of insulin and a global leader in diabetes care.
Its product portfolio includes insulin, GLP-1 receptor agonists, and related devices for managing diabetes, as well as medicines for obesity, haemophilia, and growth disorders. Novo Nordisk has played a significant role in advancing therapies for metabolic diseases and continues to expand research into cardiovascular and rare conditions.
The company operates production facilities in several countries, with key research and development centres located in Denmark, the United States, China, the United Kingdom and India. Its medicines are marketed in more than 170 countries.
Novo Nordisk is listed on the Nasdaq Copenhagen stock exchange and also has American Depositary Receipts (ADRs) traded on the New York Stock Exchange (NYSE).
Data provided by 
Saxo provides this content for general information only. It is not intended as personal advice, an offer, or a recommendation. Saxo does not guarantee accuracy or completeness and accepts no liability for losses. Consider obtaining independent advice before any investment decision.
Others were interested in
See all stocksFrequently asked questions
To buy Novo Nordisk B A/S stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Novo Nordisk B A/S by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Novo Nordisk B A/S is NOVOb:xcse. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Novo Nordisk B A/S has its primary listing on NASDAQ OMX Copenhagen. You can trade Novo Nordisk B A/S with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Novo Nordisk B A/S is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Novo Nordisk B A/S as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Novo Nordisk B A/S or others.